NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

603707

CNE100002WP3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
11.12 ^CNY	+1.09%		-2.63%	-25.87%

01/07	Nanjing King-Friend Biochemical Pharma Registers Regadenoson Injection in China; Shares Up 3%	MT
28/06	NKFPharma's Unit Buys Yusimry's Rights for $40 Million	MT

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Subsidiary's Product Obtaining Medicine Registration Certificate for Bendamustine Hydrochloride Injection from National Medical Products Administration

January 19, 2021 at 04:03 pm IST

Nanjing King-friend Biochemical Pharmaceutical Co. Ltd. announced that Subsidiary's Product Obtaining Medicine Registration Certificate for Bendamustine Hydrochloride Injection from National Medical Products Administration.

Latest news about Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Nanjing King-Friend Biochemical Pharma Registers Regadenoson Injection in China; Shares Up 3%	01/07	MT
NKFPharma's Unit Buys Yusimry's Rights for $40 Million	28/06	MT
Nanjing King-Friend Biochemical Pharmaceutical Gets Drug Registration Approval for Anti-Nausea Drug	26/06	MT
US FDA Approves Additional Production Site for King-Friend Biochemical Pharma's Melanoma, Hodgkin's Disease Drug	03/06	MT
Hybio Pharmaceutical Gets Nod to Market Ganirelix Acetate Injection	28/05	MT
NKFPharma's Unit Gets FDA's Nod to Market Eptifibatide Injection in US	13/05	MT
NKFPharma Gets Nod to Register New Cancer Treatment	01/05	MT
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	27/04	CI
King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection	16/01	MT
NKFPharma Gets Certificate to Register Voriconazole for Injection	11/01	MT
Nanjing King-Friend’s Cancer Drug Get US FDA Nod	28/12	MT
King-Friend Biochemical Pharma Gets Certificates for Registration of Micafungin Sodium for Injection	22/12	MT
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S	21/23/21	CI
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Nanjing King-Friend Wins FDA Nod to Market Generic Version of Aloxi in US	17/23/17	MT
NKFPharma Unit Gets US FDA's Nod for Plerixafor Injection	26/23/26	MT
NKFPharma Unit Gets US FDA Nod for Cancer Drug	21/23/21	MT
NKFPharma Unit Gets FDA Greenlight to Market Anesthetic in the US	27/23/27	MT
NKFPharma Unit Gets FDA Nod for US Registration of Rocuronium Bromide	10/23/10	MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
NKFPharma Gets Certification for Lung Cancer Drug	11/23/11	MT
NKFPharma's Nadroparin Calcium Injection Passes Drug Regulator’s Evaluation	21/23/21	MT
Nanjing King-friend Unit’s Anti-Cancer Drug Enters US Market	15/22/15	MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	28/22/28	CI

Chart Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Duration

Period

Chart Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

More charts

Company Profile

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of heparin-related products. The Company's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The Company mainly exports its products to the United States and European countries.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.12 CNY

Average target price

16.78 CNY

Spread / Average Target

+50.94%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.	-25.87%	2.47B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.04%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ROCHE HOLDING AG	+12.68%	250B
ASTRAZENECA PLC	+16.30%	247B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals